Unique advantages of the ABS2 blood sampling system include:

  • Undiluted samples, verified by in-line sensors
  • A short collection path, to minimize mixing and collection times
  • Less than five µL of blood wasted per sample, to minimize hemodilution
  • The flexibility to work with a range of species, from mice and rats to large animals

This second-generation autosampler builds on the proven foundation of a series of precision peristaltic pumps to move blood and IV fluids directly to their destinations. The fraction collector has been redesigned from the ground up for additional features and high reliability.

The ABS2 not only works with refrigerated vials (such as Sarstedt Microvette tubes), but also can deposit 10-25µL microsamples directly onto dried blood spot paper.

Automated Blood Sampler (ABS2)

Ordering Information

ABS is part of the "Be Nice" family. Are you?

I Want To Be Nice

Literature

Please contact us to request copies.

Gantert, L. et al, Merck & Co., Inc., "Automated Arterial Blood Sampling in Rhesus Monkey PET Imaging Studies," presentation at Infusion Technology Organisation conference, Cologne Germany, 7 September 2015. See Poster

Kenny J. et al, Merck & Co., Inc., "Utilization of Mouse Automated Blood Sampling (ABS) for Serial Plasma Pharmacokinetic (PK) Studies," poster presentation at AALAS TriBranch Symposium, Atlantic City, 9 June 2015.

Galgosi A., Merck & Co., "Automated Blood Sampling in Rats; Practical Considerations," presentation at Harlan DMPK Seminar, Frankfurt Germany, 8 June 2011.

Uyeda C., Fide S. et al, Amgen Inc., "Evaluation of Automated Blood Sampling for Low Volume Serial Sampling and Dried Blood Spot Pharmacokinetic Applications in Mouse and Rat," poster P218 at AALAS conference, San Diego CA, 4 October 2011.

Uyeda C., Pham R., Fide S., Henne K,. Xu G., Soto M., James C., Wong P, Amgen Inc., "Application of automated dried blood spot sampling and LC–MS/MS for pharmacokinetic studies of AMG 517 in rats," Bioanalysis (2011) 3(20), pages 2349–2356.

C. Schnell, T. Ferrat, D. Wyss, W. Tinetto, S. Tobler, C. Fritsch & M.R. Jensen, "Circadian timing regimen for alpelisib (BYL719), a selective inhibitor of the class Ia PI3K isoform alpha to maximize therapeutic index," See Poster